Literature DB >> 23754164

Study of osteoporosis treatment principles used historically by ancient physicians in Chinese Medicine.

Zhen Gao1, Yong Lu, Jing Jing, Dan Xu.   

Abstract

OBJECTIVE: To review the herbal drugs most often used throughout history for the treatment of osteoporosis; to study their property, flavor and meridian attribution; and to explore their compatibility.
METHODS: The "Chinese Medical Classics" (upgrade) CD-ROM was used to retrieve historical prescriptions for the treatment of osteoporosis, and these were collected and sorted. Property, flavor and meridian attribution were determined, and the rules of herbal administration were determined by cluster analysis.
RESULTS: A total of 389 prescriptions were found, involving 238 herbal drugs, with a total frequency of appearance of 4,236. Commonly used medications were Radix Achyranthis Bidentatae, Radix Rehmanniae praeparata, Cortex Cinnamomi, Cortex Eucommiae, Poria, Herba Cistanches, Radix Aconiti lateralis and Radix Angelicae sinensis. The herbs used included five kinds of properties, appearing a total of 2,499 times; the two most common ones were warm and plain. There were seven different drug flavors, occurring 4,151 times; sweet and bitter were the two most common ones. Eight meridian attributions were identified, appearing a total of 6,374 times; Kidney (Shen)-meridian and Liver (Gan)-meridian were the two most common ones. The most common functional categories were yang-tonifying medicinal and blood-tonifying medicinal, and together these accounted for 37.8% of the total. The twenty-eight most commonly used herbal drugs formed 3 prescription clusters: C1: Cortex Eucommiae, Poria, Radix Achyranthis Bidentatae; C2: Cortex Eucommiae, Poria, Radix Achyranthis Bidentatae, Cortex Cinnamomi, Radix Rehmanniae praeparata, Herba Cistanches, Radix Angelicae sinensis, Radix Aconiti lateralis, Semen Cuscutae; C3: Os Tigris, Rhizoma Atractylodes Alba, Radix Moromdae Officinalis, Radix Angelicae pubescentis, Radix Paeoniae Alba, Herba Dendrobii, Rhizoma Alismatis, Fructus Corni, Radix Saposhnikoviae.
CONCLUSIONS: Deficiency is the primary pathogenetic factor in osteoporosis, along with "stagnation" and lack of flow of water or blood. Clinical treatment of osteoporosis should be based on Kidney, Liver and Spleen (Pi) supplementation, and complemented by diuresis and dissolution of stasis, while paying attention to adjustment of the spirit.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23754164     DOI: 10.1007/s11655-013-1328-z

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  10 in total

1.  Effect of serum from postmenopausal women with osteoporosis exhibiting the Kidney-Yang deficiency pattern on bone formation in an hFOB 1.19 human osteoblastic cell line.

Authors:  Yachan Li; Wenna Liang; Xihai Li; Bizhen Gao; Huijuan Gan; Lianhua Yin; Jianying Shen; Jie Kang; Shanshan Ding; Xuejuan Lin; Linghong Liao; Candong Li
Journal:  Exp Ther Med       Date:  2015-07-03       Impact factor: 2.447

2.  Radix Rehmannia Glutinosa inhibits the development of renal fibrosis by regulating miR-122-5p/PKM axis.

Authors:  Xinhua Liu; Honglan Xu; Yunhua Zang; Weiguo Liu; Xiangbo Sun
Journal:  Am J Transl Res       Date:  2022-01-15       Impact factor: 4.060

Review 3.  Cistanche Deserticola for Regulation of Bone Metabolism: Therapeutic Potential and Molecular Mechanisms on Postmenopausal Osteoporosis.

Authors:  Cheng Wang; Feng Li; Yang Li; Hui Feng; Min-Wei Zhao; Peng-Fei Tu; Hua Tian
Journal:  Chin J Integr Med       Date:  2022-08-05       Impact factor: 2.626

Review 4.  Evolving Roles of Natural Terpenoids From Traditional Chinese Medicine in the Treatment of Osteoporosis.

Authors:  Yue Zhuo; Meng Li; Qiyao Jiang; Hanzhong Ke; Qingchun Liang; Ling-Feng Zeng; Jiansong Fang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-16       Impact factor: 6.055

5.  N-Butanol Extract of Modified You-Gui-Yin Attenuates Osteoclastogenesis and Ameliorates Osteoporosis by Inhibiting RANKL-Mediated NF-κB Signaling.

Authors:  Qinghe Zeng; Rui Xu; Houfu Ling; Shan Zhao; Xu Wang; Wenhua Yuan; Mancang Gu; Taotao Xu; Pinger Wang; Hongfeng Ruan; Hongting Jin; Hangbo Qu; Fusheng Ye; Jiali Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-24       Impact factor: 6.055

6.  The Efficacy and Safety of Traditional Chinese Medicine Tonifying-Shen (Kidney) Principle for Primary Osteoporosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Junquan Liang; Fengyi Wang; Jiajia Huang; Yunxiang Xu; Guizhen Chen
Journal:  Evid Based Complement Alternat Med       Date:  2020-10-06       Impact factor: 2.629

7.  An analysis of the combination frequencies of constituent medicinal herbs in prescriptions for the treatment of bone and joint disorder in Korean medicine: determination of a group of candidate prescriptions for universal use.

Authors:  Yoo Kyoung Han; Seo Yul Kim; Jae Young Ahn; Jin Ung Baek
Journal:  Integr Med Res       Date:  2017-09-19

Review 8.  Fructus Ligustri Lucidi in Osteoporosis: A Review of its Pharmacology, Phytochemistry, Pharmacokinetics and Safety.

Authors:  Beibei Chen; Lili Wang; Lin Li; Ruyuan Zhu; Haixia Liu; Chenyue Liu; Rufeng Ma; Qiangqiang Jia; Dandan Zhao; Jianzhao Niu; Min Fu; Sihua Gao; Dongwei Zhang
Journal:  Molecules       Date:  2017-09-05       Impact factor: 4.411

9.  Preventive effects of Polygonum multiflorum on glucocorticoid-induced osteoporosis in rats.

Authors:  Manru Zhou; Jin Li; Jingkai Wu; Yajun Yang; Xiaobing Zeng; Xiaohua Lv; Liao Cui; Weimin Yao; Yuyu Liu
Journal:  Exp Ther Med       Date:  2017-07-18       Impact factor: 2.447

10.  Haimufang decoction, a Chinese medicine formula for lung cancer, arrests cell cycle, stimulates apoptosis in NCI-H1975 cells, and induces M1 polarization in RAW 264.7 macrophage cells.

Authors:  Wei-Ping Ma; Shu-Man Hu; Yan-Lai Xu; Hai-Hua Li; Xiao-Qing Ma; Bao-Hong Wei; Fu-Yu Li; Hua-Shi Guan; Guang-Li Yu; Ming Liu; Hong-Bing Liu
Journal:  BMC Complement Med Ther       Date:  2020-08-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.